Nilo Therapeutics emerged from stealth with a $101 million Series A to develop therapeutics that modulate neural circuits governing systemic immune homeostasis. Founded by labs at Columbia, Yale and Harvard, Nilo will advance programs based on vagal and other brain‑immune pathways identified in Charles Zuker’s and colleagues’ work. The round was led by The Column Group, DCVC Bio and Lux Capital with strategic investors including the Gates Foundation and Alexandria Venture Investments. CEO Kim Seth and CSO Laurens Kruidenier will build a New York R&D hub and expand preclinical programs aimed at autoimmune and inflammatory diseases. The financing funds laboratory build‑out and preclinical validation; investors framed the approach as a way to coordinate multiple immune pathways via ‘master regulator’ circuits rather than single cytokine targets. Nilo’s launch underscores investor appetite for neuro‑immunology, an area linking neuroscience discovery to systemic immunomodulation.